Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 14/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 3/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6644636 | 0.86 | SRC (0.38) | SRCCSF1RMAP4K4EGFRERBB2 | |
| SCHEMBL14361196 | 0.84 | SRC (0.39) | SRCKCNH2CSF1RMAP4K4EGFR | |
| SCHEMBL2819930 | 0.82 | CSF1R (0.40) | SRCKCNH2CSF1RMAP4K4EGFR | |
| SCHEMBL22013370 | 0.82 | KCNH2 (0.38) | SRCKCNH2CSF1RMAP4K4EGFR | |
| SCHEMBL3374333 | 0.80 | CSNK1A1 (0.38) | SRC | |
| SCHEMBL24569769 | 0.80 | CSNK1A1 (0.40) | SRCEGFR | |
| SCHEMBL28867703 | 0.80 | PTPN11 (0.38) | KCNH2MAP4K4EGFR | |
| SCHEMBL2032213 | 0.79 | CSF1R (0.44) | KCNH2CSF1R | |
| SCHEMBL3272833 | 0.79 | CSF1R (0.38) | SRCKCNH2CSF1RMAP4K4EGFR | |
| SCHEMBL4502318 | 0.77 | KCNH2 (0.43) | KCNH2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233827-B1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | ACRAF (IT) | 2020-07-08 | — | — | EP | disclosed |
| EP-3233827-B1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | ACRAF (IT) | 2020-07-08 | — | — | EP | disclosed |
| US-10221144-B2 | Antibacterial compounds having broad spectrum of activity | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2019-03-05 | — | — | US | disclosed |
| US-10221144-B2 | Antibacterial compounds having broad spectrum of activity | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2019-03-05 | — | — | US | disclosed |
| US-20170369450-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-12-28 | — | — | US | disclosed |
| US-20170369450-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2017-12-28 | — | — | US | disclosed |
| EP-3233827-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | Aziende Chimiche Riunite Angelini Francesco A.C.R. (IT) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096686-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096686-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2016-06-23 | — | — | WO | disclosed |
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070254872-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20070161627-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| EP-1796466-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-06-20 | — | — | EP | disclosed |
| EP-1784410-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-05-16 | — | — | EP | disclosed |
| EP-1773831-A1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-04-18 | — | — | EP | disclosed |
| WO-2007016610-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
| WO-2006020561-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006014580-A1 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006002047-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | NPM1, TOP1, HMGB1 | SRC 3684/4885KCNH2 3440/4885CSF1R 2839/4885 |
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | PAICS, SBDS, SORD | SRC 1949/4885KCNH2 1381/4885CSF1R 3805/4885 |
| US-20170369450-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | MRPL21, ABCG2, CLPP | SRC 4119/4885KCNH2 3274/4885CSF1R 2539/4885 |
| US-10221144-B2 | Antibacterial compounds having broad spectrum of activity | MRPL21, ABCG2, CLPP | SRC 4119/4885KCNH2 3274/4885CSF1R 2539/4885 |
| US-20070161627-A1 | Antibacterial agents | NQO2, NQO1, NDUFV2 | SRC 4810/4885KCNH2 2586/4885CSF1R 2626/4885 |
| US-20070254872-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | SRC 4810/4885KCNH2 2586/4885CSF1R 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.